Belantamab Mafodotin, Pomalidomide, Dexamethasone: Indication: Belantamab mafodotin is indicated, in combination with pomalidomide and dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including lenalidomide: Reimbursement Recommendation

What is the reimbursement recommendation for blenrep?Canada’s Drug Agency (CDA-AMC) recommends that Blenrep in combination with pomalidomide and dexamethasone be reimbursed by public drug plans for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 1 prior line of therapy, including lenalidomide, if certain conditions are met. WHICH PATIENTS ARE ELIGIBLE FOR COVERAGE? Blenrep in combination with pomalidomide and dexamethasone should only be covered to treat adults with relapsed or refractory multiple myeloma who are in relatively good health and have already tried at least 1 other lenalidomide-containing regimen for this disease. Blenrep in combination with pomalidomide and dexamethasone should not be reimbursed in patients who were previously treated with an anti-BCMA therapy or pomalidomide. WHAT ARE THE CONDITIONS FOR REIMBURSEMENT? Blenrep in combination with pomalidomide and dexamethasone should only be reimbursed if it is prescribed under the care of a clinician with expertise in the diagnosis and management of patients with multiple myeloma, and the cost of Blenrep is reduced. WHY DID CDA-AMC MAKE THIS RECOMMENDATION? • Evidence from a clinical trial demonstrated that Blenrep in combination with pomalidomide and dexamethasone may delay disease progression and prolong life in adults with relapsed or refractory multiple myeloma compared to bortezomib in combination with pomalidomide and dexamethasone. • Blenrep meets some patient needs as it is an alternative treatment option that may offer disease control benefits. • Based on the CDA-AMC assessment of the health economic evidence, Blenrep does not represent good value to the health care system at the public list price. A price reduction is therefore required. • Based on public list prices, Blenrep is estimated to cost the public drug plans approximately $485 million over the next 3 years. However, the actual budget impact is uncertain and will depend on several factors, including real-world dosing patterns, the extent of uptake across jurisdictions, and the distribution of subsequent therapies in the treatment pathway.Additional informationWHAT IS MULTIPLE MYELOMA? Multiple myeloma is a cancer of plasma cells (the white blood cells that make immunoglobulins) in the bone marrow. In 2024, it was estimated that 4,100 people in Canada were diagnosed with multiple myeloma. UNMET NEEDS IN MULTIPLE MYELOMA: Multiple myeloma is an incurable disease, and patients commonly experience relapse or have disease that eventually becomes refractory to treatment. There is a need for additional effective therapies that can prolong survival, delay disease progression, and improve quality of life. HOW MUCH DOES BLENREP COST? Treatment with Blenrep in combination with pomalidomide and dexamethasone is expected to cost approximately $58,249 per 28 days per patient in the first cycle, and $49,909 per 28 days per patient in subsequent cycles.